TNFAIP8抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08892(TNFAIP8 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08892(TNFAIP8 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

TNFAIP8 (Tumor Necrosis Factor Alpha-Induced Protein 8) is a family of proteins involved in regulating cell survival, apoptosis, and immune responses. It plays dual roles in cancer and inflammation, acting either as an oncogene or tumor suppressor depending on cellular context. TNFAIP8 promotes cell proliferation, metastasis, and chemoresistance in various cancers by modulating signaling pathways like PI3K/AKT and NF-κB. In immunity, it regulates T-cell activation and inflammatory responses, linking it to autoimmune diseases and infections.

TNFAIP8 antibodies are critical tools for studying its expression, localization, and function. These antibodies (monoclonal or polyclonal) are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and flow cytometry to quantify TNFAIP8 levels in tissues or cell lines. Researchers employ them to explore TNFAIP8’s role in tumor progression, immune evasion, and therapy resistance. Commercially available antibodies often target conserved regions, with validation across species like human, mouse, and rat.

Recent studies highlight TNFAIP8 as a potential biomarker for cancer prognosis and a therapeutic target. Antibodies against TNFAIP8 also aid in developing diagnostic assays and evaluating experimental inhibitors. However, specificity and cross-reactivity challenges require careful validation. Understanding TNFAIP8’s mechanisms through antibody-based research remains pivotal for advancing cancer immunology and targeted therapies.